One gene, two important proteins

September 14, 2002

When the Human Genome Project first revealed last year that humans possess only an estimated 30,000 genes - fives times more than a mustard weed plant - the fact that many genes code for more than just one protein assumed greater importance. Such protein variations, researchers reasoned, must play an even larger role in contributing to the remarkable complexity of human beings.

This notion has been supported recently by Rockefeller University scientists, who report the discovery of a novel protein variation within a single fruit fly gene, or "gene locus." Specifically, they show that the fly's one and only "STAT" gene locus - the human counterpart of which plays a role in cancer - codes for a second protein that inhibits the activity of the originally characterized STAT protein.

"In this post-genomic era, findings like this one make it more and more clear that alternate proteins, or protein isoforms, should be considered when attempting to explain complex biological phenomena," says James E. Darnell Jr., Ph.D., principal author of the report published in the Sept. 15 issue of Genes and Development.

The discovery of an inhibitory STAT protein suggests possible novel treatments for the approximately 50 percent of human cancers in which STAT proteins are known to be overactive. These include leukemia, breast cancer and head and neck cancer.

Other authors of this research paper include first authors Melissa A. Henriksen, Ph.D., and Aurel Betz, Ph.D., and second author Marc V. Fucillo, all from The Rockefeller University. Darnell is the head of the Laboratory of Molecular Cell Biology at Rockefeller and co-author of the popular textbook Molecular Cell Biology.

The STAT genes, first identified by the Darnell laboratory in 1992, code for a set of proteins that help cells throughout the body to interpret and respond to dozens of incoming chemical messages. They are found in a variety of organisms, from slime molds to humans, and are essential to many aspects of life, including growth and immunity.

Yet, despite their versatile nature, only a handful of STAT genes exist: seven have been identified in humans, four of these by Darnell's group, and just one has been found in flies, also by Darnell and colleagues.

One of the key questions in biology is how a single gene or a limited set of genes, like the STATs, can respond to such a diverse array of molecular signals with an equally diverse set of biological outcomes. The new research provides one answer by not only identifying a second protein encoded within the only STAT gene locus in flies - but by showing that it has an important inhibitory action on the original STAT protein and its various roles in developmental events.

Moreover, this particular finding marks a first in the field of STAT research. "Though an increasing number of other types of STAT inhibitors have been identified, this is the first time that a functional one has been found within the STAT gene itself," says Henriksen.

Molecular Transmitters

A lone liver cell placed into a petri dish will lose its identity, while a liver cell living amongst its kind will thrive. Darnell first observed this phenomenon in the early 1980s and concluded that molecular cues from a cell's natural environment must control the production of tissue-specific proteins. The next big question was how.

Over the next decade or so, he and colleagues provided more than an answer by mapping out the first complete "signal transduction" pathway. They showed that an incoming molecular message, such as a polypeptide hormone or cytokine, binds to a receptor located on the outside of a cell, which then leads to the activation of a "kinase" enzyme called "JAK." JAK, in turn, activates the STAT proteins ("Signal Transducers and Activators of Transcription"), which subsequently travel to the nucleus, bind to specific patches of DNA and switch on corresponding genes - the end result being the production of new proteins.

Today, scientists know that the JAK-STAT pathway faithfully relays the messages of at least 40 different molecular signals, including interferon, growth hormone, prolactin, erythropoeitin and most of the interleukins - and thus constitutes one of the body's primary means of communicating with its vast multitude of cells. What happens when this communication goes awry was demonstrated by Darnell, Jacqueline Bromberg, Henriksen and other colleagues in 1999. They showed that a human STAT protein, called STAT3 - which is overactive in various human tumors - can by itself turn normal cells into cancerous ones. The finding marked STAT3 as an official "oncogene" and solidified the notion that drugs designed to block the action of STATs may prove beneficial to cancer patients.

Two for Price of One

According to the Central Dogma of biology, DNA codes for a messenger molecule called RNA, which then codes for proteins. Since the late 1970s, scientists have known that the standard unit of DNA - the gene or gene locus - can and often does code for multiple functional proteins. This variation in coding ability comes from alternate RNA "start" sites or alternate splicing choices, that is choices in the way RNA is processed into a protein. However, these alternate proteins, or protein isoforms, have not perhaps received as much attention as they deserve.

In the new study, the researchers discovered that the only known STAT gene in flies, called Stat92E, codes for a second, shorter protein in addition to the originally characterized, longer form. They then found that this new, short protein is missing an important region of the long protein - the same region required for its activity. This finding led them to ask if the purpose of the short protein was to inhibit the action of the long by usurping its molecular targets.

This type of inhibition, known as a "dominate negative," may be better understood by picturing a key unable to open a lock because another broken one is jammed inside: the broken key (short protein) prevents the right key (active protein) from opening the lock (activating molecular targets).

To test this theory, the researchers turned to developing fly embryos. Normally, a fly embryo develops in a segmented fashion: seven stripes containing a protein called "even-skipped" form along the length of its body, dividing the embryo into eight segments. From previous experiments, the researchers knew that a defective STAT92E gene will cause these stripes, and thus the body segments, to disappear and the resulting larvae to become irregular.

As predicted, when the researchers overproduced the short STAT92E protein - or when they reduced the amount of the long STAT92E protein - the embryo's body segments disappeared. These experiments, reported in the current Genes and Development, demonstrate that this new, alternate STAT is indeed a negative regulator of STAT92E activity.

In the same paper, they also showed that the ratio of the short to the long protein changed significantly as the fly developed.

"This kind of variation in overall STAT activity immediately suggests a mechanism by which one STAT gene can control so many different processes," says Betz.

Currently, the researchers are testing whether this same mechanism is conserved in humans. Says Darnell, "It seems unlikely that such a potentially valuable mechanism of gene regulation would be discarded in evolution."
-end-
Founded by John D. Rockefeller in 1901, The Rockefeller University was this nation's first biomedical research university. Today it is internationally renowned for research and graduate education in the biomedical sciences, chemistry, bioinformatics and physics. A total of 21 scientists associated with the university have received the Nobel Prize in medicine and physiology or chemistry, 16 Rockefeller scientists have received Lasker Awards, have been named MacArthur Fellows and 11 have garnered the National Medical of Science. More than a third of the current faculty are elected members of the National Academy of Sciences.

Rockefeller University

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.